Viking Therapeutics Inc (VKTX) concluded trading on Wednesday at a closing price of $27.09, with 4.16 million shares of worth about $112.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.71% during that period and on June 25, 2025 the price saw a gain of about 0.52%. Currently the company’s common shares owned by public are about 112.29M shares, out of which, 108.99M shares are available for trading.
Stock saw a price change of 2.50% in past 5 days and over the past one month there was a price change of 0.41%. Year-to-date (YTD), VKTX shares are showing a performance of -48.63% which decreased to -32.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $18.92 but also hit the highest price of $81.73 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 3.79 million. The stock is currently trading 0.04% above its 20-day simple moving average (SMA20), while that difference is up 0.60% for SMA50 and it goes to -33.61% lower than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 112.29M outstanding shares and institutions hold larger chunk of about 69.46% of that.
The stock has a current market capitalization of $3.04B and its 3Y-monthly beta is at 0.63. It has posted earnings per share of -$1.15 in the same period. It has Quick Ratio of 44.25 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 5.31% while standing at 3.83% over the month.
Analysts are in expectations that Viking Therapeutics Inc (VKTX) stock would likely to be making an EPS of -0.44 in the current quarter, while forecast for next quarter EPS is -0.48 and it is -2.49 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.55 which is -0.37 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -86.96% while it is estimated to decrease by -35.97% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on April 29, 2025 offering an Overweight rating for the stock and assigned a target price of $104 to it. Coverage by Goldman stated Viking Therapeutics Inc (VKTX) stock as a Neutral in their note to investors on April 08, 2025, suggesting a price target of $30 for the stock. On February 13, 2025, Scotiabank Initiated their recommendations, while on February 07, 2025, Citigroup Initiated their ratings for the stock with a price target of $38. Stock get an Overweight rating from Piper Sandler on December 02, 2024.
